Clinical trials: Gastrointestinal Stromal Tumors (GISTs)
Solid Tumors
Expanded Access Program for Avapritinib
This record comprises the currently available Expanded Access Programs (EAP) for avapritinib (BLU-285): 1) A Post Trial Access (PTA) program to provide continued access to treatment with avapritinib to BLU-285-1107 participants…
- Trial name
- NCT04714086
- Testing
- Avapritinib
- Sponsor
- Blueprint Medicines Corporation
GIST
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with…
- Trial name
- NCT03465722
- Testing
- avapritinib, regorafenib
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 476 people
- Sponsor
- Blueprint Medicines Corporation
Gastrointestinal Stromal Tumors
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
- Trial name
- NCT00812240
- Testing
- Masitinib, Imatinib
- Where
- 41 sites in United States, France and 1 more
- Volunteers
- 335 people
- Sponsor
- AB Science
Advanced Gastrointestinal Stromal Tumors
A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
Open-label, multicenter study of imatinib (400mg/die p.o.)in patients with advanced gastrointestinal stromal tumors. Patients will be treated for up to 12 months.
- Trial name
- NCT00940563
- Testing
- Imatinib
- Where
- 26 sites in Italy
- Volunteers
- 135 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Cancer
Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)
This study will determine the safety and effectiveness of AMG 706 in patients with advanced GIST.
- Trial name
- NCT00089960
- Testing
- AMG 706
- Volunteers
- 138 people
- Sponsor
- Amgen
Gastrointestinal Stromal Tumors
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Gastrointestinal stromal tumors (GIST) compose approximately 20% of soft tissue sarcomas with an annual incidence of approximately 7 per million population.
- Trial name
- NCT04106024
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Cttq
Gastrointestinal Stromal Tumors
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
This is an open label, multi-center, phase II study of BBI503 administered to adult patients with advanced gastrointestinal stromal tumor who have exhausted all currently approved standard anti-cancer treatment options.
- Trial name
- NCT02232620
- Testing
- BBI503
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Sumitomo Pharma America, Inc.
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, Neuroendocrine Neoplasm of Lung, Thymic Neuroendocrine Neoplasm
- Trial name
- NCT06523582
- Where
- 3 sites in Mexico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Gastrointestinal Stromal Tumors
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
Primary objectives 1. To determine whether induction of apoptosis or inhibition of angiogenesis are involved in the antitumor activity of (Gleevec, Formerly STI-571) in patients with gastrointestinal stromal tumors (GIST) as…
- Trial name
- NCT00500188
- Testing
- Imatinib Mesylate (Gleevec)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric GIST
Study On Safety Of Endoscopic Resection For 2-5cm Gastric Gastrointestinal Stromal Tumor
This research is a prospective, multi-center trial for endoscopic resection and laparoscopic partial gastrectomy in patients with 2-5cm gastric gastrointestinal stromal tumor.
- Trial name
- NCT04751591
- Testing
- Endoscopic resection, Laparoscopic partial gastrectomy
- Volunteers
- 260 people
- Sponsor
- Shanghai Zhongshan Hospital
GIST
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is a US, multicenter, open-label expanded access program to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.
- Trial name
- NCT03862885
- Testing
- Avapritinib
- Sponsor
- Blueprint Medicines Corporation
Upper Gastrointestinal Submucosal Tumors (SMTs), Gastrointestinal Stromal Tumors (GISTs)
ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors
The purpose of this study is to determine the efficacy and safety of endoscopic submucosal tunnel dissection (ESTD) compared with video-assisted thoracoscopic surgery (VATS) in the treatment of upper gastrointestinal submucosal…
- Conditions
- Upper Gastrointestinal Submucosal Tumors (SMTs), Gastrointestinal Stromal Tumors (GISTs), Leiomyoma
- Trial name
- NCT01768104
- Testing
- ESTD, VATS
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastrointestinal Stromal Tumor
the Laparoscopic and Endoscopic Cooperative Surgery of Gastrointestinal Stromal Tumor
Gastric stromal tumor is a gastrointestinal mesenchymal tumor with malignant differentiation potential, the incidence increased year by year. The surgical resection is the primary treatment for it.
- Trial name
- NCT02763748
- Testing
- Laparoscopic endoscopy combined surgery, laparoscopic and endoscopic cooperative surgery, Single-arch laparoscopic and endoscopic cooperative surgery
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
GIST
A Study of Olverembatinib in SDH-deficient GIST.
An international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously…
- Trial name
- NCT06640361
- Testing
- Olverembatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ascentage Pharma Group Inc.
Gastrointestinal Stromal Tumor, Malignant
Entacapone Combination With Imatinib for Treatment of GIST
This study evaluates the combination of entacapone and imatinib in the treatment of gastrointestinal stromal Tumors who have progressed on the setting of at least Imatinib and Sunitinib.
- Trial name
- NCT04006769
- Testing
- Entacapone, Imatinib Mesylate
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Xiangya Hospital of Central South University
Gastrointestinal Stromal Tumor
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Oblimersen may help imatinib mesylate kill more tumor cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00091078
- Testing
- oblimersen sodium, imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Metastatic Cancer
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and to see how well it works…
- Trial name
- GISTs (NCT00764595)
- Testing
- imatinib mesylate
- Where
- 36 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Gastrointestinal Stromal Tumors
Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting.
- Trial name
- NCT00877045
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- SCRI Development Innovations, LLC
Gastrointestinal Stromal Tumor
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily.
- Trial name
- NCT00372567
- Testing
- sunitinib malate, imatinib mesylate
- Where
- 25 sites in United States, Germany and 5 more
- Volunteers
- 69 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumor
Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination
Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.
- Trial name
- MACS2226 (NCT01613053)
- Testing
- Glivec
- Where
- 3 sites in China
- Sponsor
- Novartis Pharmaceuticals